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patients with mild/moderate (n  = 17), severe/very severe 
(n = 16) stable COPD, control smokers (n = 16), control non-
smokers (n = 9), in mild asthma (n = 9) and in peripheral air-
ways from COPD patients (n = 15) and control smokers (n = 
15). Interleukin (IL)-8 and MAPK mRNA was measured in 
stimulated 16HBE cells.  Results: No significant differences in 
p-p38 MAPK, p-JNK or p-ERK1/2 expression were seen in 
bronchial biopsies and peripheral airways between COPD 
and control subjects. Asthmatics showed increased submu-
cosal p-p38 MAPK expression compared to COPD patients 
(p < 0.003) and control non-smokers (p < 0.05). Hydrogen 
peroxide (H 2 O 2 ), cytomix (tumour necrosis factor-α + IL-1β + 
interferon-γ) and lipopolysaccharide (LPS) upregulated IL-8 
mRNA at 1 or 2 h. p38 MAPKα mRNA was significantly in-
creased after H 2 O 2 and LPS treatment. JNK1 and ERK1 mRNA 
were unchanged after H 2 O 2 , cytomix or LPS treatments.  Con-
clusion: p-p38 MAPK expression is similar in stable COPD 
and control subjects but increased in the bronchi of mild 
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 Abstract 
 Background: The role of mitogen-activated protein kinases 
(MAPK) in regulating the inflammatory response in the air-
ways of patients with chronic obstructive pulmonary disease 
(COPD) and asthmatic patients is unclear.  Objectives: To in-
vestigate the expression of activated MAPK in lungs of COPD 
patients and in bronchial biopsies of asthmatic patients and 
to study MAPK expression in bronchial epithelial cells in re-
sponse to oxidative and inflammatory stimuli.  Methods: Im-
munohistochemical expression of phospho (p)-p38 MAPK, 
p-JNK1 and p-ERK1/2 was measured in bronchial mucosa in 
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asthmatics compared to stable COPD patients. p38 MAPK 
mRNA is increased after bronchial epithelial challenges in vi-
tro. These data together suggest a potential role for this 
MAPK in Th2 inflammation and possibly during COPD exac-
erbations.  © 2015 S. Karger AG, Basel 
 Introduction 
 The mitogen-activated protein kinase (MAPK) family 
includes 3 distinct stress-activated protein kinase path-
ways: p38, c-Jun N-terminal kinase (JNK) and extracel-
lular regulating kinase (ERK)  [1] . The ERK pathway is 
predominantly activated by mitogenic and proliferative 
stimuli, whereas the JNK and p38 MAPK respond to en-
vironmental stresses  [1] . A potential role of activated p38 
MAPK has been reported for neutrophil and eosinophil 
lung cell migration, cytokine release from inflammatory 
cells and airway smooth muscle, release of matrix metal-
loproteinases, Th1 cell differentiation and interferon 
(IFN)-γ production and induction of corticosteroid in-
sensitivity  [2] . MAPK and the pro-inflammatory tran-
scription factor nuclear factor-κB (NF-κB) are activated 
in airway epithelial cells and macrophages exposed to dif-
ferent stimuli such as lipopolysaccharide (LPS), cigarette 
smoke extracts and oxidants  [3–8] . The production of 
mucin by airway epithelial cells is induced by oxidants 
and is accompanied by p38 MAPK phosphorylation and 
activation  [6] . Cigarette smoke exposure of airway epi-
thelial cells resulted in upregulation of interleukin (IL)-6 
and IL-8 mediated by p38 MAPK and NF-κB  [9] . Rhino-
virus exposure of human macrophages induces p38 
MAPK activation and release of CCL1 (monocyte che-
moattractant protein-1)  [10] . Increased phospho (p)-p38 
MAPK immunopositivity was reported in lung alveolar 
septa of chronic obstructive pulmonary disease (COPD) 
patients when compared to control smokers and non-
smokers  [11] , whilst p-p38 MAPK expression in lympho-
cytes within the submucosa of peripheral airways was 
similar in COPD patients, control smokers and non-
smokers  [12] . In bronchial biopsies of asthmatics, epithe-
lial staining for p-p38 MAPK and p-ERK1/2 was in-
creased compared to healthy controls, while healthy sub-
jects showed the highest p-JNK intensity  [13] . MAPK 
expression and activation have not been studied to date 
in bronchial biopsies of COPD patients. Due to the role 
of p38 MAPK in inducing inflammation, p38 MAPK in-
hibitors have recently been studied, particularly in severe 
asthmatics and COPD patients  [2] . The results obtained 
in these clinical trials are not particularly encouraging 
 [14–16] .
 In COPD, the airflow limitation is usually progressive 
and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases  [17, 18] . Previ-
ous studies have emphasized the potential role of p38 
MAPK in the pathogenesis of COPD and asthma  [2] . 
However, the mechanisms of inducing p38 MAPK up-
regulation and its participation in the inflammatory state 
in the bronchi of COPD patients are not yet fully clarified.
 The present study aimed: (1) to quantify by immuno-
histochemistry the activated MAPK expression in the 
bronchial biopsies and peripheral airways of patients with 
COPD and to compare these findings with control smok-
ers, non-smoking subjects and a group of asthmatics, and 
(2) to investigate MAPK mRNA expression in vitro in 
bronchial epithelial cells in response to oxidative (H 2 O 2 ) 
and inflammatory (LPS, cytomix) stimuli which are im-
plicated in COPD and asthma.
 Methods 
 Subjects 
 All COPD and healthy control subjects who underwent bron-
choscopy and bronchial biopsy collection were recruited from the 
Respiratory Medicine Unit of the Fondazione Salvatore Maugeri 
(Veruno, Italy). Asthmatics were recruited from the Division of 
Pneumology, Ospedale San Luigi, Orbassano, University of Tori-
no, and the severity of asthma was classified according to the GINA 
and ATS criteria  [19, 20] . In COPD patients, the severity of the 
airflow obstruction was staged using current GOLD criteria (www.
goldcopd.com). All former smokers had stopped smoking for at 
least 1 year. COPD and chronic bronchitis were defined, according 
to international guidelines, as follows: COPD, presence of a post-
bronchodilator forced expiratory volume in 1 s (FEV 1 )/forced vital 
capacity (FVC) ratio <70%; levels of shortness of breath, chronic 
cough, sputum and numbers of exacerbations per year were also 
taken into account as suggested by new GOLD criteria; chronic 
bronchitis, presence of cough and sputum production for at least 
3 months in each of 2 consecutive years  [18] . All COPD patients 
were stable with no previous exacerbation in the 6 months before 
bronchoscopy. None of the COPD patients was treated with the-
ophylline, antibiotics, antioxidants, mucolytics and/or glucocorti-
coids in the month prior to the bronchial biopsy. The peripheral 
lung tissues were collected at the University Hospital of Ferrara, 
during lung resection for a solitary peripheral neoplasm, and all 
subjects were not under regular treatment with glucocorticoids 
and/or bronchodilators. Asthmatics were under therapy following 
GINA criteria  [19] . The study conformed to the Declaration of 
Helsinki and was approved by the ethics committees of the Fon-
dazione Salvatore Maugeri, Veruno (Novara), San Luigi Hospital, 
Orbassano (Torino), and the University Hospital of Ferrara, Italy; 
written informed consent was obtained from each participant, and 
bronchial biopsies were performed according to the guidelines of 
the local ethics committee.
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 Lung Function Tests and Volumes 
 Pulmonary function tests were performed as previously de-
scribed  [21] according to guideline recommendations  [22] . Pul-
monary function tests included measurements of FEV 1 and FEV 1 /
FVC under baseline conditions in all the subjects examined (6200 
Autobox Pulmonary Function Laboratory; Sensormedics Corp., 
Yorba Linda, Calif., USA). In order to assess the reversibility of 
airflow obstruction and postbronchodilator functional values, the 
FEV 1 and FEV 1 /FVC percent measurements in the groups of sub-
jects with FEV 1 /FVC  ≤ 70% before bronchodilator use was repeat-
ed 20 min after the inhalation of 0.4 mg of salbutamol.
 Fibre-Optic Bronchoscopy, Collection and Processing of 
Bronchial Biopsies 
 Subjects were at the bronchoscopy suite at 8.30 a.m. after hav-
ing fasted from midnight and were pretreated with atropine (0.6 
mg i.v.) and midazolam (5–10 mg i.v.). Oxygen (3 l/min) was ad-
ministered via nasal prongs throughout the procedure, and oxygen 
saturation was monitored with a digital oximeter. Using local an-
aesthesia with lidocaine (4%) to the upper airways and larynx, a 
fibre-optic bronchoscope (Olympus BF10 Key-Med, Southend, 
UK) was passed through the nasal passages into the trachea. Fur-
ther lidocaine (2%) was sprayed into the lower airways, and 4 bron-
chial biopsy specimens were taken from segmental and subseg-
mental airways of the right lower and upper lobes using size 19 
cupped forceps. Bronchial biopsies for immunohistochemistry 
were gently extracted from the forceps and processed for light mi-
croscopy as previously described  [21] . At least 2 samples were em-
bedded in Tissue Tek II OCT (Miles Scientific, Naperville, Ill., 
USA), frozen within 15 min in isopentane precooled in liquid ni-
trogen and stored at –80  °  C. The best frozen sample was then ori-
ented, and 6-μm-thick cryostat sections were cut for immunohis-
tochemical light microscopy analysis and processed as described 
below.
 Collection and Processing of the Peripheral Lung Tissue 
 Thirty subjects undergoing lung resection surgery for a solitary 
peripheral neoplasm were recruited. Fifteen were smokers with 
normal lung function, and 15 subjects were smokers with COPD 
(table 3). All former smokers had stopped smoking for more than 
1 year. No subject underwent pre-operative chemotherapy and/or 
radiotherapy and had been treated with bronchodilators, theoph-
ylline, antibiotics, antioxidants and/or glucocorticoids in the 
month prior to surgery. Lung tissue processing was performed as 
previously described  [23, 24] . Two to 4 randomly selected tissue 
blocks were taken from the subpleural parenchyma of the lobe ob-
tained at surgery, avoiding areas grossly invaded by tumour. Sam-
ples were fixed in 4% formaldehyde in phosphate-buffered saline 
(PBS) at pH 7.2 and, after dehydration, embedded in paraffin wax. 
Serial sections 4 μm thick were first cut and stained with haema-
toxylin-eosin in order to visualize the morphology and to exclude 
the presence of microscopically evident tumour infiltration. Tissue 
specimens were then cut for immunohistochemical analysis and 
were placed on charged slides as previously reported  [24] .
 Immunohistochemistry on OCT-Embedded Bronchial Biopsies 
 One cryostat section from each biopsy was stained applying 
immunohistochemical methods with a panel of antibodies specif-
ic for inflammatory cells (CD4+, CD8+, CD68+, neutrophil elas-
tase+) or p-MAPK ( table 1 ). Briefly, after blocking non-specific 
binding sites with serum derived from the same animal species as 
the secondary antibody, primary antibody was applied at optimal 
dilutions in Tris-buffered saline (0.15  M saline containing 0.05  M 
Tris-hydrochloric acid at pH 7.6) and incubated for 1 h at room 
temperature in a humid chamber. Antibody binding was demon-
strated with secondary anti-mouse (Vector, BA 2000) or anti-rab-
bit (Vector, BA 1000) antibodies followed by ABC kit AP AK5000 
Vectastain and fast red substrate (red colour) or ABC kit HRP 
Elite, PK6100, Vectastain and diaminobenzidine substrate (brown 
colour). Human tonsils or nasal polyps were used as positive con-
trols. For the negative control, normal mouse or rabbit non-spe-
cific immunoglobulins (Santa Cruz Biotechnology, Santa Cruz, 
Calif., USA) were used at the same protein concentration as the 
primary antibody.
 Immunohistochemistry in Human Peripheral Lung Tissue 
 Immunostaining of paraffin-embedded peripheral lung tissue 
was performed as previously described  [23] . After deparaffinization 
and rehydration to expose the immunoreactive epitopes, the sec-
tions to be stained, immersed in retrieval solution citrate, pH 6.0, or 
EDTA, pH 8.0, were incubated in a microwave oven (model NN 
S200W; Panasonic, Milano, Italy) on high power for 40 min. Endog-
enous peroxidase activity was blocked by incubating slides in 3% 
H 2 O 2 in PBS followed by washing in PBS. Cell membranes were 
permeabilized adding 0.1% saponin to the PBS. Non-specific label-
ling was blocked by coating with  blocking serum (5% normal goat 
serum) for 20 min at room temperature. After washing in PBS the 
sections were treated with the following primary antibodies: rabbit 
monoclonal p-p38 MAPK (p-Thr180/p-Tyr182; code 1229-1) and 
rabbit p-ERK1/p-ERK2 (p-Thr202/p-Tyr204; code 1229-1), both 
 Table 1.  Primary antibodies and immunohistochemical conditions used for identification of MAPK and inflammatory cells
Primary antibody Origin ID Secondary antibody Dilution Positive control
p-p38 Santa Cruz SC-17852-R Rabbit 1:150 Nasal polyp, human tonsil
p-JNK1 Abcam Ab-18680 Rabbit 1:150 Nasal polyp, human tonsil
p-ERK1/2 Epitomics 1481-1 Rabbit 1:100 Nasal polyp, human tonsil
CD4 Dako M716 Mouse 1:100 Nasal polyp, human tonsil
CD8 Dako M7103 Mouse 1:200 Nasal polyp, human tonsil
CD68 Dako M814 Mouse 1:200 Nasal polyp, human tonsil
Neutrophil elastase Dako M752 Mouse 1:100 Nasal polyp, human tonsil
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obtained from Epitomics, and mouse monoclonal anti-p-SAPK/
JNK (Thr183/Tyr185; www.scbt.com; code sc6254) at the dilution 
of 1.25, 1: 50 and 1: 300, respectively. Sometimes we have used differ-
ent primary antibodies for the immunohistochemical and the West-
ern blotting (see below) studies because the cell signalling technol-
ogy does not provide the concentration of their primary antibody, 
and this does not allow the use of appropriate negative controls 
(non-specific IgG at the same concentration of the primary anti-
body) for immunohistochemical studies. For the negative control 
slides normal rabbit or mouse non-specific immunoglobulins (San-
ta Cruz Biotechnology) were used at the same protein concentration 
as the primary antibody. Control slides were included in each stain-
ing run using human normal tonsils (kindly provided by Prof. Ste-
fano Pelucchi, ENT Section at the University of Ferrara, Italy) as a 
positive control for all the immunostaining performed. After re-
peated washing steps with PBS, the sections were subsequently in-
cubated with goat anti-rabbit or horse anti-mouse biotinylated an-
tibody (Vector ABC Kit, Vector Laboratories; www.vectorlabs.com) 
for 30 min at room temperature. After further washing, the sections 
were subsequently incubated with ABC reagent (Vector ABC kit, 
Vector Laboratories) for 30 min at room temperature. Slides were 
then incubated with chromogen-fast diaminobenzidine as chromo-
genic substance, after which they were counterstained in haema-
toxylin and mounted on permanent mounting medium.
 Scoring System for Immunohistochemistry in the Bronchial 
Biopsies 
 Morphometric measurements were performed with a light mi-
croscope (Leitz Biomed, Leica, Cambridge, UK) connected to a 
video recorder linked to a computerized image system (Quanti-
met 500 Image Processing and Analysis System, Software Qwin 
V0200B, Leica). Light-microscopic analysis was performed at a 
magnification of ×630.
 The immunostaining for all antigens studied was scored (range: 
from 0 = absence of immunostaining to 3 = extensive intense im-
munostaining) in the intact (columnar and basal epithelial cells) 
bronchial epithelium, as previously described  [21] . The final result 
was expressed as the average of all scored fields performed in each 
biopsy. A mean ± SD of 0.700 ± 0.260 mm of epithelium was ana-
lysed in COPD patients and control subjects. Immunostained cells 
in bronchial biopsy lamina propria were quantified 100 μm be-
neath the epithelial basement membrane in several non-overlap-
ping high-power fields until the whole specimen was examined. 
The final result, expressed as the number of positive cells per 
square millimetre, was calculated as the average of all the cellular 
counts performed in each biopsy.
 Scoring System for Immunohistochemistry in the Peripheral 
Lung Tissue 
 Staining analysis was performed as previously described  [24] . 
Staining data were interpreted blinded with no prior knowledge of 
the clinicopathological parameters. A bronchiole was taken to be 
an airway with no cartilage and glands in its wall. To count the 
number of positive cells on the sections stained for p-p38 MAPK, 
p-JNK and p-ERK, the area of bronchiolar epithelium to be studied 
was selected randomly. Cells with nuclear immunostaining were 
counted on each of 10 consecutive, non-overlapping, high-power 
fields (about 300 cells) with 1 count on each of 3, when available, 
bronchioles for each section stained. Results were expressed as per-
centages of total bronchiolar epithelial cells counted.
 To quantify kinase expression in alveolar macrophages, at least 
20 high-power fields of lung parenchyma were randomly selected 
for each section, and at least 100 macrophages inside alveoli were 
evaluated. Alveolar macrophages were defined as mononuclear 
cells with well-represented cytoplasm present in the alveolar spac-
es and not attached to the alveolar walls using a previously vali-
dated method  [25] . Results were expressed as percentages of total 
alveolar macrophages counted.
 Western Blot Analysis for p-p38 MAPK, p-JNK and p-ERK in 
the Peripheral Lung 
 Whole cell protein extraction from peripheral lung parenchy-
ma, gel electrophoresis and nitrocellulose filter transfer were per-
formed as previously described  [21] . After blocking for 45 min at 
room temperature in Tris-buffered saline, 0.05% Tween-20 and 
5% non-fat dry milk, filters were incubated with rabbit anti-p-
p38 MAPK (Cell Signalling, monoclonal antibody No. 9215) or 
rabbit anti-p-JNK1 (Abcam, Ab-18680) or rabbit anti-p-pERK1/2 
(Epitomics, 1481-1) for 1 h at room temperature in Tris-buffered 
saline, 0.05% Tween-20 and 5% non-fat dry milk at a dilution of 
1: 500 to 1: 1,000 (0.1–0.2 mg/ml). HeLa cells were used as positive 
controls. After washing, filters were incubated with goat anti-
rabbit (Dako, UK) antibody conjugated to horseradish peroxi-
dase at a dilution of 1: 4,000. Visualization was performed using 
enhanced chemiluminescence as recommended by the manufac-
turer (Amersham Pharmacia Biotech). Anti-human actin anti-
body (Santa Cruz Biotechnology) was used as an internal control. 
Bands were quantified using densitometry with Grab-It and 
 VisionWorks LS software (UVP, Cambridge, UK) and expressed 
as a ratio with the corresponding actin optical density value of the 
same line.
 Cell Culture and Treatments 
 We used the SV40 large T antigen-transformed 16HBE cell line 
that retains the differentiated morphology and function of normal 
human bronchial epithelial cells  [26] . For experiments 16HBE cells 
were passaged using Dulbecco’s modified minimum essential me-
dium (DMEM), supplemented with 10% v/v fetal bovine serum 
(FBS), 50 IU/ml penicillin, 50 μg/ml streptomycin, 1× non-essen-
tial amino acids, 1 m M sodium pyruvate and 2 m M glutamine 
(37  °  C, 5% CO 2 ). When cells were at 60–70% confluence, the com-
plete medium was replaced with DMEM without FBS for starva-
tion time (24 h), followed by DMEM plus 1% FBS in the absence 
or presence of H 2 O 2 (100 μ M ), cytomix (TNF-α 10 ng/ml + IL-1β 
1 ng/ml + IFN-γ 10 ng/ml; R&D System), LPS from  Pseudomonas 
aeruginosa (Sigma, L9143; 10 μg/ml), at 1, 2 and 4 h. Passage num-
bers of cells used in this study ranged from 22 to 24. All experi-
ments were performed at least in quadruplicate for 4 independent 
experiments for each type of treatment (H 2 O 2 , cytomix, LPS) and 
each time of exposure (1, 2, 4 h).
 Extraction and Quantification of RNA and qRT-PCR from 
16HBE 
 Total cellular RNA from exposed and non-exposed cultures 
was purified and isolated using an RNAspin Mini RNA Isolation 
kit (GE Healthcare) following the manufacturer’s instructions. To-
tal RNA was resuspended in 100 μl nuclease-free water. RNA con-
centration was determined using a UV/visible spectrophotometer 
(λ 260/280 nm, Eppendorf BioPhotometer plus) and stored at 
–80  °  C.
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 The expression of genes of interest was measured using Syber 
green (Qiagen, UK) for qPCR in a Corbett Rotor Gene 6 (Corbett, 
Cambridge, UK) system. One-step real-time PCR was carried out 
by amplifying mRNA using the QuantiFast TM Syber green RT-
PCR kit (Qiagen, Italy) according to the manufacturer’s instruc-
tions and the gene specific primers (Qiagen, Italy). We detected 
the expression of CXCL8 (IL-8; cat. QT00000322, Qiagen), p38α 
(cat. QT00079345), JNK1 (cat. QT00091056), ERK1 (cat. 
QT00065933) and NF-κB p65 (cat. QT01007370) mRNA after 
each stimulation. We performed independent experiments and 
quantitative PCR measurements in quadruplicate for each type of 
treatment (H 2 O 2 , cytomix, LPS) and each 16HBE time of expo-
sure (1, 2, 4 h). A single qPCR determination was performed for 
each type of treatment and time of exposure. Briefly, the PCR re-
action mix, prepared in a total volume of 25 μl, was run on the 
Rotor Gene Q (Qiagen, Italy), and the following PCR run protocol 
was used: 55  °  C for 10 min (reverse transcription); 95  °  C for 5 min 
(PCR initial activation step); 40 amplification cycles of 95   °   C for 
5 s (denaturation) and 60  °  C for 10 s (combined annealing/exten-
sion), followed by melting curve analysis to ensure the specificity 
of PCR amplification. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; QT01192646, Qiagen) was used as the reference 
gene for every target gene per sample, and the data were normal-
ized against the respective GAPDH signalling. Cycle threshold 
values were determined using the Rotor Gene Q software (Rotor-
Gene Q Series Software 2.0.2). The expression levels of all genes 
studied were normalized to GAPDH levels in each sample to de-
termine the expression between treated and non-treated cells us-
ing the 2 –ΔC t method  [27] .
 Statistical Analysis 
 Group data were expressed as mean (with standard deviation) 
for functional data and median (with range) or interquartile range 
for morphological data. Differences between groups were analysed 
using analysis of variance (ANOVA) for functional data. The 
ANOVA test was followed by the unpaired t test for comparison 
between groups. The Kruskal-Wallis test applied for morphologi-
cal data was followed by the Mann-Whitney U test for comparison 
between groups. In vitro data were expressed as means ± standard 
deviation and analysed by the t test. Correlation coefficients were 
calculated using the Spearman rank method. Probability values of 
p < 0.05 were considered significant. Data analysis was performed 
using the Stat View SE Graphics program (Abacus Concepts Inc., 
Berkeley, Calif., USA).
 Results 
 Clinical Characteristics of Subjects Studied by 
Immunohistochemistry 
 We obtained and studied bronchial biopsies from 58 
subjects: 33 with stable COPD, 16 were current or ex-
smokers with normal lung function, and 9 were non-
smokers with normal lung function ( table 2 ). COPD pa-
tients were divided into 2 groups: mild/moderate (GOLD 
stage I–II, n = 17) and severe/very severe (GOLD stage 
III–IV, n  = 16; www.goldcopd.com). Subjects in all 4 
groups were age-matched. The smoking history was sim-
ilar in the 3 smoking groups. Values of FEV 1 (% predict-
ed) and FEV 1 /FVC (%) were significantly different in the 
groups with mild/moderate and severe/very severe COPD 
compared to both control groups (healthy smokers and 
healthy non-smokers). Severe/very severe COPD patients 
also differed significantly from mild/moderate COPD pa-
tients (for overall groups, ANOVA test: p  < 0.0001 for 
FEV 1 % predicted and FEV 1 /FVC % values). Thirty-six 
percent (n = 12) of the total COPD patients and 25% (n = 
4) of healthy smokers with normal lung function also had 
symptoms of chronic bronchitis. There was no significant 
difference when COPD patients and healthy smokers 
were compared for the presence of chronic bronchitis. 
For comparative purposes related to the expression of p-
 Table 2.  Clinical characteristics of COPD, asthmatics and control subjects studied by bronchial biopsy analysis
Groups n Age,
years
M/F Pack-
years
Ex/current
smokers
FEV1 before 
BD, % pred.
FEV1 after 
BD, % pred.
FEV1/
FVC, %
Control non-smokers 9 64±10 8/1 0 0 112±15 n.d. 89±12
Control smokers with normal lung function 16 60±9 11/5 43±29 4/12 100±13 n.d. 81±6
COPD stages I and II (mild/moderate) 17 71±8c 14/3 50±28 6/11 63±11a 67±13 57±9a
COPD stages III and IV (severe/very severe) 16 70±16c 10/6 59±39 12/4 36±8a, b 43±9 43±11a, b
Asthmatics 9 66±8 5/4 0 – 85±17 97±17 81±10
 Patients were classified according to GOLD (http://www-goldcopd.com) levels of severity for COPD into mild (stage I), moderate (stage 
II), severe (stage III) and very severe (stage IV). Mild asthmatics were classified according to the GINA and ATS criteria. Data are means ± 
SD. For COPD and asthmatic patients FEV1/FVC (%) are postbronchodilator values. M = Male; F = female; BD = bronchodilator; n.d. = not 
determined. Statistics (ANOVA): a p < 0.0001, significantly different from control smokers with normal lung function and control never-
smokers; b p < 0.0001, significantly different from mild/moderate COPD; c p < 0.05, significantly different from control smokers with normal 
lung function.
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6
MAPK in the bronchi of COPD patients and asthmatics, 
we also studied bronchial biopsies from 9 stable age-
matched mildly asthmatic patients. Clinical characteris-
tics of asthmatics are included in  table 2 . Asthmatics were 
using short-acting bronchodilators on demand. Two out 
of 9 asthmatics were using inhaled corticosteroids at low 
doses.
 We studied peripheral lung specimens from 15 stable 
COPD patients and 15 control smokers with normal lung 
function matched for their age and smoking history 
 ( table 3 ).
 Measurement of Inflammatory Cells in the Bronchial 
Submucosal Biopsies of COPD Patients 
 These data, obtained from stable COPD patients by 
immunohistochemistry, confirm previously reported 
higher numbers of neutrophils and CD8+ cells in severe/
very severe COPD ( table  4 )  [28] . COPD patients with 
chronic bronchitis had a similar number of neutrophils 
when compared with COPD patients without chronic 
bronchitis  [21, 28] .
 p-MAPK Immunohistochemistry in Bronchial Biopsies 
and Peripheral Airways 
 Immunohistochemistry in the Bronchial and 
Bronchiolar Epithelium and Alveolar Macrophages 
 In COPD and control subjects the most frequently ex-
pressed activated MAPK in bronchial epithelium was 
p-p38 MAPK. p-JNK1 was occasionally expressed in 
bronchial epithelium whereas p-ERK1/2 was virtually ab-
sent. Scored values for p-p38 MAPK and p-JNK1 did not 
show any significant differences between groups ( table 4 ). 
No significant differences were observed for p-p38 MAPK 
between asthmatics (median 0.75, range 0.25–1.5) and 
 Table 4.  Immunohistochemical quantification of inflammatory cells and MAPK related to inflammatory response in bronchial mucosa
Control
non-smokers
Control smokers Mild/moderate
COPD
Severe/very
severe COPD
Kruskal-Wallis 
p value
Epithelium (score 0–3)
p-p38 0.75 (0.25–1) 0.75 (0.25–1.25) 0.5 (0.25–1.25) 0.5 (0.25–1.5) 0.618
p-JNK1 0.12 (0–0.25) 0.1 (0–1) 0.12 (0–1) 0.25 (0–1) 0.521
p-ERK1/2 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) n.a.
Submucosa, cells/mm2
p-p38 89 (27–118) 105 (32–155) 52 (20–106) 49 (27–161) 0.223
p-JNK1 5 (0–20) 7 (0–45) 17 (0–64) 11 (3–51) 0.262
p-ERK1/2 0 (0–6) 0 (0–21) 0 (0–13) 0 (0–2) 0.212
CD4 164 (101–212) 246 (37–500) 258 (107–731) 252 (66–470) 0.206
CD8 147 (76–301) 179 (86–657) 195 (86–523) 244 (111–355)a 0.365
CD68 284 (128–516) 275 (97–904) 367 (158–759) 340 (204–1,054) 0.671
Neutrophil elastase 93 (58–166) 97 (45–308) 94 (28–512) 151 (47–470)a, b 0.045
 n.a. = Not applicable. Data expressed as medians (ranges). Statistics: the Kruskal-Wallis test was used for multiple comparisons fol-
lowed by the Mann-Whitney U test for comparison between groups; a p < 0.05, significantly different from control non-smokers; b p < 
0.05, significantly different from control smokers with normal lung function; the exact p values for comparison between groups are 
given in the Results section.
 Table 3.  Characteristics of subjects for the immunohistochemistry and Western blotting studies on the peripheral lung tissue
Subjects n Age, years M/F Ex/current 
smokers
Pack-years Chronic
bronchitis (yes/no)
FEV1, % pred. FEV1/FVC, %
Control smokers 15 66±7 12/3 8/7 40±34 7/8 100.3±15.6 77±3.7
COPD patients 15 69±7 13/2 8/7 42±22 7/8 72.4±20* 58±9.7*
 Data are expressed as means ± SD. M = Male; F = female. For COPD patients and smokers with normal lung function, FEV1 and 
FEV1/FVC are postbronchodilator values. Statistics (ANOVA): * p < 0.001, significantly different from control smokers with normal 
lung function.
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7
control non-smokers (p  = 0.958), severe/very severe 
COPD (p = 0.385), mild/moderate COPD (p = 0.247) or 
all COPD patients (p = 0.249;  fig. 1 ). Similarly, no sig-
nificant differences were observed for p-JNK1 between 
asthmatics (median 0.125, range 0–0.25) and control 
non-smokers (p = 0.957), severe/very severe COPD (p = 
0.270), mild/moderate COPD (p = 0.345) or all COPD 
patients (p = 0.256). No significant differences were ob-
served for p-ERK1/2 between asthmatics (median 0, 
range 0–0) and control non-smokers (p > 0.999), severe/
very severe COPD (p  > 0.999), mild/moderate COPD 
(p > 0.999) or all COPD patients either (p > 0.999).
 Immunohistochemistry in the Bronchial Submucosal 
Biopsies 
 In COPD and control subjects the most frequently ex-
pressed MAPK in bronchial submucosa was, as for epi-
thelium, p-p38 MAPK. It was mainly expressed by mono-
nuclear cells and occasionally by endothelial cells.  p-JNK1 
was poorly expressed in all groups studied, and p-ERK1/2 
was only occasionally found. In COPD patients and con-
trol subjects no significant differences between groups 
were observed for all p-MAPK studied ( table 4 ;  fig. 2 ). 
Interestingly, asthmatics showed higher levels of p-p38 
MAPK protein (median 125, range 54–387) when com-
pared to control non-smokers (p = 0.040), severe/very 
severe COPD (p  = 0.013), mild/moderate COPD (p  = 
0.0018) or all COPD patients (p = 0.0016;  fig. 1 ). No sig-
nificant differences were observed for p-JNK1/mm 2 
counted in asthmatics (median 13, range 5–161) when 
compared to control non-smokers (p = 0.112), severe/
very severe COPD (p  = 0.654), mild/moderate COPD 
(p = 0.571) or all COPD patients (p = 0.570). No signifi-
cant differences were observed for p-ERK1/2/mm 2 
 Fig. 1. Photomicrographs showing the bronchial mucosa from an 
asthmatic subject ( a ) and a patient with COPD ( b ) immunostained 
for identification of p-p38+ cells (arrows). Results are representa-
tive of those from 33 (mild/moderate and severe/very severe) 
COPD patients and 9 mild asthmatics. Column bar graphs indicate 
median (and interquartile range) values of p-p38 scored in the ep-
ithelium ( c ) and p-p38+ cells quantified in the submucosa ( d ) of 
all COPD patients (n = 33) and asthmatics (n = 9) studied. p values 
are based on the Mann-Whitney test for comparison between 
groups. 
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 Fig. 2. Photomicrographs showing the bronchial mucosa from 
control non-smokers ( a–c ) and patients with mild/moderate 
COPD ( d–f ) immunostained (arrows) for identification of p-p38 
( a ,  d ), p-JNK1 ( b ,  e ) and p-ERK1/2 ( c ,  f ) in the bronchial epithe-
lium and submucosa. Results are representative of those from 9 
non-smokers and 33 COPD patients.  g Negative control immu-
nostaining, performed in a nasal polyp section, including an irrel-
evant rabbit primary antibody. 
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9
counted between asthmatics (median 5, range 0–17) 
and  control non-smokers (p  = 0.216), mild/moderate 
COPD (p = 0.608) or all COPD patients (p = 0.156). A 
slight but significant increase was observed in asthmat-
ics  in comparison with severe/very severe COPD (p  = 
0.034).
 Immunohistochemistry in the Peripheral Lung 
Tissue 
 In the peripheral airways no significant differences 
were observed for percentages of p-p38 MAPK immu-
nostained bronchiolar epithelial cells between COPD 
(median 68, range 10–100) and control smokers (70, 
range 40–100; p = 0.9181). Percentages of p-p38 MAPK+ 
alveolar macrophages in COPD (median 87, range 60–
100) versus control smokers (94, range 82–100; p  = 
0.5265) were not significantly different either ( fig. 3 ).
 No significant differences were observed for percent-
ages of p-JNK immunostained bronchiolar epithelial cells 
between COPD (median 38, range 2–64) and control 
smokers (36, range 5–58; p = 0.5439). Percentages of p-
JNK+ alveolar macrophages in COPD (median 88, range 
60–100) versus control smokers (90, range 40–100; p = 
0.3216) were not significantly different ( fig. 4 ).
 No significant differences were observed for percent-
ages of p-ERK1/2-immunostained bronchiolar epithe-
lial cells between COPD (median 40, range 0–90) and 
control smokers (37, range 0–70; p = 0.5495). Percent-
 Fig. 3.  a Western blot analysis of activated p-p38 MAPK in snap-
frozen peripheral lung lysates of stable COPD (n  = 9) and age-
matched control smokers with normal lung function (n = 7) with 
actin as the control for loading.  b Graphical analysis of the densi-
tometric ratio (arbitrary units, AU) of p-p38 MAPK/actin.  c Im-
munohistochemical images of p-p38 MAPK immunostaining in 
bronchiolar epithelial cells and alveolar macrophages representa-
tive of 15 COPD and 15 control smokers. Magnification ×400. 
Bar = 50 μm.  d ,  e Graphical presentation of the percentage of epi-
thelial and macrophage staining. 
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ages of p-ERK1/2+ alveolar macrophages in COPD (me-
dian 75, range 25–100) versus control smokers (72, 
range 8–100; p = 0.8682) were not significantly different 
either ( fig. 4 ).
 Western Blotting for p-p38 MAPK, p-JNK and 
p-ERK1/2 in Peripheral Lung Tissue 
 No significant differences were observed for the p-p38 
MAPK/actin ratio between COPD (median 1.02, range 
0.2–1.40) and control smokers (1.0, range 0.65–1.30; p = 
1.0000;  fig. 3 ), the p-JNK/actin ratio between COPD (me-
dian 0.10, range 0.05–0.13) and control smokers (0.10, 
range 0.06–0.12; p  = 0.4079;  fig.  4 ) and the p-ERK1/2/
actin ratio between COPD (median 0.10, range 0.05–
0.13) and control smokers (0.10, range 0.06–0.12; p  = 
0.4079;  fig. 4 ).
 Correlations between p-MAPK Cell Counts, Clinical 
Parameters and Inflammatory Cells in the Bronchial 
Biopsies 
 In all smokers and in patients with COPD alone we did 
not observe any significant correlation between numbers 
of p-p38+, p-JNK1+ and p-ERK1/2+ cells per square mil-
limetre and numbers of cigarettes smoked (pack-years), 
functional (spirometry values and clinical parameters) 
data or structural (inflammatory cells) data.
 MAPK, NF-κB p65 and IL-8 mRNA Expression in 
16HBE Cells Induced by Oxidative and Inflammatory 
Stimuli in vitro 
 Human bronchial epithelial (16HBE) cells were stim-
ulated with H 2 O 2 (100 μ M ), cytomix (TNF-α, 10 ng/ml, 
IL-1β, 1 ng/ml, and IFN-γ, 10 ng/ml) and LPS (10 μg/
ml), and the expression of IL-8 ( fig.  5 a), p38 MAPKα 
( fig. 5 b), JNK1 ( fig. 5 c), ERK1 ( fig. 5 d) and NF-κB p65 
subunit ( fig.  5 e) mRNA was quantified by qRT-PCR. 
IL-8 mRNA was significantly increased 2 h after H 2 O 2 
(p < 0.0001), 1 and 2 h after cytomix (p = 0.001 and p = 
0.017, respectively), and 2 h after LPS (p = 0.043;  fig. 5 a). 
p38 MAPKα mRNA was significantly increased 2 h after 
H 2 O 2 (p = 0.030) and 1 h after LPS (p = 0.010) but it did 
not change after cytomix treatment ( fig.  5 b). JNK1 
mRNA was not significantly changed by any of the treat-
ments used ( fig. 5 c). ERK1 mRNA was not significantly 
increased after H 2 O 2 , cytomix or LPS treatments ( fig. 5 d). 
NF-κB p65 subunit mRNA was significantly increased 
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 Fig. 4. Graphical presentation of the percentage of p-ERK1/2-im-
munostained bronchiolar epithelial cells ( a ), percentage of p-
ERK1/2-immunostained positive macrophages ( b ) and p-
ERK1/2/actin ratio from peripheral lung lysates ( c ), percentage of 
p-JNK-immunostained bronchiolar epithelial cells ( d ), percent-
age of p-JNK-immunostained positive macrophages ( e ) and p-
JNK/actin ratio from peripheral lung lysates ( f ) in stable COPD 
and control smokers. AU = Arbitrary units. Data are representa-
tive of 15 stable COPD and 15 control smokers for immunohisto-
chemical data and 9 stable COPD and 7 control smokers for West-
ern blot analysis. The Mann-Whitney test was used for compari-
son between groups. 
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 Fig. 5. In vitro expression of CXCL8 (IL-8;  a ), p38α ( b ), JNK1 ( c ), 
ERK1 ( d ) and NF-κB p65 subunit ( e ) mRNA in 16HBE cells treat-
ed with H 2 O 2 (100 μ M ), cytomix (TNF-α, 10 ng/ml, IL-1β, 1 ng/ml, 
and IFN-γ, 10 ng/ml) and LPS from  P. aeruginosa . All treatments 
upregulated IL-8 mRNA expression 1 or 2 h after treatment ( a ). 
H 2 O 2 stimulation upregulated p38 ( b ) and p65 ( e ) mRNA 2 h after 
stimuli. LPS upregulated p-38 ( b ) mRNA 1 h after stimulus. All 
experiments were performed in quadruplicate. Data are expressed 
as means ± standard deviation. Statistical analysis: t test ( *  p < 0.05) 
for comparison between treated (TR) and non-treated (NT) cells. 
The exact p values for comparison between groups are given in the 
Results section. 
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2 h after H 2 O 2 (p = 0.032) but it did not reach statistical 
significance 2 h after cytomix (p = 0.086) and LPS (p = 
0.093;  fig. 5 e).
 Discussion 
 This study shows similar immune expression of p-p38 
MAPK, p-JNK1 and p-ERK1/2 in the bronchial epitheli-
um and submucosa of patients with mild/moderate and 
severe/very severe stable COPD when compared to con-
trol smokers and control non-smokers. Activated MAPK 
were also similarly expressed in the bronchiolar epithe-
lium of stable COPD patients compared to control smok-
ers with normal lung function. p-p38 MAPK immu-
nopositivity in the bronchial submucosa of asthmatics 
was significantly increased when compared to stable 
COPD and control non-smokers. Interestingly, bronchi-
al epithelial cells (16HBE) exposed in vitro to H 2 O 2 , cyto-
mix and LPS showed increased levels of IL-8 mRNA pro-
duction which were accompanied by a parallel increase in 
p38 MAPK mRNA after H 2 O 2 and LPS stimulation but 
not by a parallel increase in JNK1 and ERK1 mRNA. In 
patients with COPD, p-p38 MAPK immunopositivity 
was increased in the small airway epithelium  [12] when 
compared to control non-smokers  [12] and in alveolar 
septa  [11] when compared to control smokers and non-
smokers  [11] . p-p38 MAPK immunopositivity in lym-
phocytes populating the submucosa of peripheral airways 
of COPD patients was similar to that found in control 
smokers and non-smokers  [12] . These last data are in part 
in agreement with our present observations of no chang-
es of p-p38 MAPK immunopositivity in the bronchial bi-
opsy submucosa of stable COPD patients compared to 
control smokers and non-smokers, peripheral airway 
bronchiolar epithelium of stable COPD patients com-
pared to control smokers, and with our observation of the 
absence of significant changes in total p-p38 MAPK pro-
tein, measured by Western blot, using lung tissue, when 
comparing stable COPD patients and control smokers 
with normal lung function. In fact, p-p38 MAPK immu-
nopositivity in our bronchial biopsy specimens was main-
ly observed in mononuclear cells and occasionally in en-
dothelial cells, and in agreement with Gaffey et al.  [12] , 
the mononuclear cell component expressing p-p38 
MAPK immunopositivity was similar in COPD patients 
and control subjects. At variance with previously report-
ed data in peripheral airways  [12] of COPD patients and 
in large airways from asthmatics  [13] , we did not find a 
significant increase in this MAPK in bronchial biopsy ep-
ithelium in mild/moderate and severe/very severe COPD 
or in peripheral tissue. This may be due, in part, to the 
presence and influence of a different inflammatory state 
of the airways when bronchial biopsies of asthmatics are 
compared to COPD patients. It is conceivable that a Th2 
prevalent inflammatory state, such as in asthma, could 
better activate MAPK, including p-p38 MAPK. To better 
understand possible differences between asthma and 
COPD, we directly compared immune expression of ac-
tivated MAPK in bronchial biopsies from COPD and 
asthmatic subjects, matched for age and sex, and we ob-
served a significant increase in p-p38 MAPK in bronchi-
al submucosa of mild asthmatics compared to stable 
COPD patients. Asthmatics also differed significantly 
from control non-smokers, confirming, in part, previous-
ly reported data  [13] . In our asthmatics we found the most 
significant difference in the submucosal area rather than 
in epithelium, as previously reported  [13] . This indicates 
that increased p-p38 MAPK levels in our asthmatics are 
mainly due to an increased infiltration of inflammatory 
cells. A Th2-type prevalent inflammation, such as in asth-
ma, may also favour the highest p-p38 MAPK expression 
observed in the bronchi of asthmatics  [29] .
 Inhalation of LPS in human volunteers induced activa-
tion of bronchial epithelium by increased expression of 
p38 MAPK and IL-8  [30] .  P. aeruginosa -challenged hu-
man bronchial epithelial cells showed increased phos-
phorylation of p38 MAPK and IL-8 gene expression 
which was reduced by the use of p38 inhibitors  [31] . Fla-
gellin from  P. aeruginosa increased the expression of IL-8 
in BEAS-2B cells compared to untreated cells, and addi-
tion of p38 MAPK inhibitors reduced IL-8 expression 
 [32] . IL-8 mRNA and protein expression was also in-
creased after LPS stimulation of bronchial epithelial cells 
 [33] . Poly(I:C) costimulation further increased IL-8 pro-
duction which was reversed by dexamethasone and a p38 
MAPK inhibitor  [33] .
 Hydrogen peroxide increased Wnt-4 and IL-8 gene ex-
pression in BEAS-2B cells  [34] . Wnt-4-stimulated 16HBE 
cells significantly increased IL-8 secretion and p38 MAPK 
activation  [35] . A lower efficacy of corticosteroids is re-
ported in human bronchial epithelial cells in asthma and 
COPD after oxidative stress challenge  [2, 36] . In paediat-
ric bronchial epithelial cells, Th2 cytokine challenge in 
the presence of rhinovirus-16 infection augmented IL-8 
release  [29] . Housedust mite-induced IL-8 release is 
blocked by an ERK inhibitor in human lung epithelial 
cells  [37] . Our in vitro experiments show that 16HBE cells 
stimulated with H 2 O 2 , cytomix and LPS upregulated IL-8 
mRNA expression, in agreement with previously report-
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ed observations  [30–37] . This was associated with upreg-
ulation of p38α MAPK but not JNK1 and ERK1 mRNA 
after H 2 O 2 and LPS exposure. Interestingly, H 2 O 2 also in-
creased NF-κB p65 mRNA. These data suggest that in 
bronchial epithelial cells the p38 MAPK pathway may be 
more relevant after LPS and oxidative stimulation.
 Our bronchial biopsy data, showing a significant in-
crease in p-p38 MAPK immune positivity in mild asth-
matics and its prevalence in stable COPD patients, taken 
together with our in vitro observations of increased p-p38 
MAPKα mRNA after bronchial epithelial stimulation 
suggests that p-p38 MAPK activation may play a signifi-
cant role in inducing bronchial inflammation in these 
diseases.
 Recently, MacNee et al.  [38] described an improve-
ment in FEV 1 after 6 weeks of p38 MAPK inhibitor treat-
ment in moderate-to-severe COPD patients. In contrast, 
a larger study, performed in moderate-to-severe stable 
COPD patients, treated with the highly selective oral p38 
MAPK inhibitor iosmapimod for 6 months, showed no 
significant changes in exercise tolerance or lung function 
 [16] . This highlights the need to better define the clinical 
phenotype of patients in order to identify a likely ‘re-
sponder’ population of COPD patients  [14, 15] . Our pres-
ent results may contribute to this scope since p-p38 
MAPK was certainly the most expressed MAPK in our 
bronchial specimens from asthmatics and COPD pa-
tients, and specific oxidative and inflammatory challeng-
es, performed in 16HBE cells, showed a significant in-
crease in p-p38 MAPKα mRNA after challenges. Since 
mononuclear cell infiltration was reported as the promi-
nent cellular type in bronchial biopsies of mild/moderate 
but not of severe/very severe COPD patients  [39] , and 
p-p38 MAPK expression, reported in the submucosa of 
bronchial biopsies, is mainly due to immunostained 
mononuclear cells, we can argue, therefore, that selected 
populations including mild-to-moderate COPD patients 
with a more inflamed airway (cut-off values for mono-
nuclear cell inflammation should be defined) and COPD 
patients during an exacerbation or those who frequently 
exacerbate, or asthmatic patients, could better respond to 
p38 MAPK inhibitors. The potential for combination 
therapies, particularly in exacerbated diseased patients, 
together with a deeper analysis of molecular events and 
possible activation of redundant inflammatory pathways, 
developing after p38 MAPK blockade, needs to be further 
studied.
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